New epilepsy company on the block wins FDA approval for made-in-Korea drug to treat focal seizures
The FDA has ushered the fifth branded drug for partial-onset seizures to the market — in what its maker calls a first for the Korean biopharma industry.
Also known as focal seizures, partial-onset seizures are defined by abnormal electrical activity in one part of the brain (versus the whole brain as in generalized seizures). While the 3 million epilepsy patients have had a swath of both prescription and generic drugs to choose from, as much as 60% continue to report having seizures. The new pill, Xcopri, promises to cut the number of episodes down to zero for some.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters